Over the past year, Hepregen has focused on ramping up our webinar schedule. Our goal is to feature one webinar per month to keep everyone apprised of up-and-coming data and applications on the HepatoPac® and HepatoMune™ platforms.
In June and July we are featuring webinars hosted by two MPCC (micro-patterned co-culture) experts; Dr. Onyi Irrechukwu, who is a scientist here at Hepregen and Dr. Sangeeta Bhatia, one of our co-founders.
On July 15th, Dr. Bhatia will be presenting on her cutting-edge research utilizing MPCCs infected with HCV and Malaria. This promises to be one of our most exciting webinars of the year.
On June 18th, Dr. Irrechukwu will present on HepatoMune. Her presentation, HepatoMune: An in vitro model for studying inflammation-drug interactions, was recently featured at our Mid-Atlantic User Group Meeting.. So, if you weren't able to attend, this would be a great time to learn more.
The feedback from our customers has been clear: You would make more use of HepatoPac if the pricing were lower. We at Hepregen have certainly seen cases where HepatoPac's improved ability to predict in vivo outcomes has saved tens, even hundreds of thousands of dollars in clinical trials, making it well worth the investment. However, we also appreciate that budgets are tight in a highly competitive market. Therefore, if you've been put off by the price of HepatoPac in the past, we invite you to contact us again. We have lowered our prices and are eager to work with new customers.
The technology behind all of our kits has been in use at Hepregen for the past 4 years. We are pleased to make it available to our customers for in-house use. Though the plates come to you in a standard format, we will continue to offer in-person training for all new customers in order to acquaint you with the proper method for handling our cultures.
One of the most promising and accurate methods of assessing liver toxicity lies with the burgeoning field of High Content Imaging technology. Hepregen's platform is highly amenable to HCI, which is why it is in use by some of the most respected scientists in the field today for this very purpose.
This recent paper details work generated by a collaboration between The Hamner Institute for Health Sciences and Hepregen.
A Micropatterned Hepatocyte Coculture Model for Assessment of Liver Toxicity Using High-Content Imaging Analysis.
O. Joseph Trask, Jr., Amanda Moore, and Edward L. LeCluyse. Assay Drug Dev
Technol., Vol. 12 (1), p 16-27, (2014).
Perhaps the most obvious symbol of Hepregen's growth over the past few months is our new look.
HepatoPac and HepatoMune are premium products, and they deserve marketing material and packaging that celebrates this.
You might have noticed that patterned hexagons are frequently featured in our new material. This is directly influenced by the technology that makes our products possible - our proprietary, architected culture patterning.
We continue to remind our customers that
"Architecture Is Important".
In May, our first Mid-Atlantic UGM brought together both experts and beginning users of Hepregen technology, including talks by customers at Pfizer, Novartis, Ricerca, and Boehringer Ingelheim.
The meeting was quite a success, as scientists were able to share their experiences with HepatoPac/HepatoMune and discuss tips, tricks, and questions.
To see what was presented and to access the presentations, click here.
We will be hosting another User Group Meeting in October in Cambridge, MA.
Be on the lookout for your invitation.
Dr. Okey Ukairo will be in Seattle for the
Drug-Drug Interactions Conference 2014 on June 30-July 2, 2014. If you are attending, be sure to stop by our booth to learn more about some of our new research and product improvements.
Enjoy this? View all our Newsletters!